Presbyopia-correcting drops provide hope for frustrated patients
Dr Cathleen McCabe describes how VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.
Dr Cathleen McCabe sits down with Sheryl Stevenson of Ophthalmology Times Europe to discuss the recently FDA-approved drops, VUITY. At AAO 2021, her presentation entitled, "GEMINI 1 and 2 pooled Phase 3 safety and efficacy: AGN-190584 primary and key secondary endpoints," discussed the finer points of the clinical trial that led to VUITY's early approval.
Allergan, a subsidiary of AbbVie, announced on October 29, 2021, that the US Food and Drug Administration (FDA) has approved pilocarpine HCl Ophthalmic Solution 1.25% for the treatment of adult patients with presbyopia.
Pilocarpine HCl ophthalmic solution 1.25% is the first and only approved eye drop to treat age-related blurry near vision.
The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Centre in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.
Related Content: Additional AAO content | Cataract & Refractive | Retina
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials
Capsulotomy creation equally safe using the manual or energy-based method
November 8th 2023A study demonstrates corneal endothelial cell density measured postoperatively does not differ whether the capsulotomy was performed using continuous curvilinear capsulorhexis (CCC) or precision pulse capsulotomy (PPC)
